A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2018-03-27
Target enrollment:
Participant gender:
Summary
This is a first-in-human and proof-of-concept study of VX-445. The study includes 6 parts.
Parts A, B, and C will be conducted in healthy subjects. Parts D, E, and F will be conducted
in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation of the CF
transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for
the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ,
IVA, or TEZ/IVA (F/MF genotypes).